AG
KYMR icon

Artal Group’s Kymera Therapeutics KYMR Stock Holding History

Artal Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,005,610
Closed -$89.7M – 54
2024
Q2 		$89.7M Sell
3,005,610
-21,525
-0.7% -$745K 2.29% 4
2024
Q1 		$122M Buy
3,027,135
+496,400
+20% +$17.8M 3.1% 4
2023
Q4 		$64.4M Buy
2,530,735
+725,389
+40% +$13M 2.14% 7
2023
Q3 		$25.1M Hold
1,805,346
– – 1.08% 16
2023
Q2 		$41.5M Hold
1,805,346
– – 1.29% 14
2023
Q1 		$53.5M Sell
1,805,346
-194,654
-10% -$6.28M 3.18% 8
2022
Q4 		$49.9M Buy
2,000,000
+500,000
+33% +$13.3M 2.79% 9
2022
Q3 		$32.7M Buy
1,500,000
+500,000
+50% +$13.2M 1.39% 22
2022
Q2 		$19.7M Hold
1,000,000
– – 1.05% 23
2022
Q1 		$42.3M Hold
1,000,000
– – 1.77% 15
2021
Q4 		$63.5M Buy
1,000,000
+600,000
+150% +$34.9M 1.72% 14
2021
Q3 		$23.5M Buy
400,000
+150,000
+60% +$8.7M 0.53% 46
2021
Q2 		$12.1M Hold
250,000
– – 0.25% 82
2021
Q1 		$9.71M Hold
250,000
– – 0.17% 100
2020
Q4 		$15.5M Hold
250,000
– – 0.33% 68
2020
Q3 		$8.08M Buy
+250,000
New +$7.63M 0.2% 82

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Artal Group's KYMR Position: Q3 2024 in Review

Artal Group sold out of Kymera Therapeutics (KYMR) in Q3 2024, closing a stake of 3,005,610 shares — an estimated $89.7M sold.

Artal Group first reported a position in KYMR in Q3 2020 and held it in 16 quarters. The position peaked at $122M in Q1 2024. 176 funds tracked by Wall St. Rank hold KYMR as of Q3 2024.

  • Artal Group reported no remaining Kymera Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 3,005,610 Kymera Therapeutics shares in Q3 2024, an estimated $89.7M.
  • Artal Group first reported a position in Kymera Therapeutics in Q3 2020 and held it in 16 quarters.
  • Artal Group's Kymera Therapeutics position peaked at $122M in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.